Know Cancer

forgot password

A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Phase 2
18 Years
Open (Enrolling)
Intracranial Meningioma

Thank you

Trial Information

A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Inclusion Criteria:

1. Patients must be 18 years of age.

2. Histologic diagnosis of meningioma, WHO grade 1, 2, or 3 (benign, atypical, or
malignant). In addition, patients with definitive radiologic evidence of meningioma
who are unresectable, and in whom radiation therapy without biopsy is the standard
treatment, are also eligible.

3. All patients must have developed recurrent disease/progression after receiving all
standard treatments, which must include the following:

- surgical resection, if possible;

- definitive radiation therapy for unresectable meningioma, or for recurrent
meningioma after resection.

- patients must be at least 4 weeks post-surgery, and must be at least 2 weeks
post-radiation therapy, with resolution of related toxicities.

4. All patients must have progressive symptoms judged to be directly related to their
recurrent/progressive meningioma. Patients with no new symptoms, or patients with
stable neurologic deficits from previous surgical resection, are not eligible.

5. Patients may have had 0 or 1 previous systemic treatment regimens.

6. ECOG performance status of 0-2.

7. Adequate bone marrow, kidney, and liver function, as follows:

- Absolute neutrophil count (ANC) ≥1500/μL

- Hemoglobin (Hgb) ≥9 g/dL

- Platelets ≥100,000/L (≤7 days prior to treatment)

- AST or ALT ≤2.5 x institutional upper limit of normal (ULN)

- Total bilirubin ≤1.5 x institutional ULN

- Serum creatinine ≤1.5 x institutional ULN

8. Life expectancy of at least 12 weeks.

9. Ability to swallow whole pills.

10. Patients must have measurable disease on MRI scan.

11. Women of childbearing potential must have a negative serum or urine pregnancy test
performed within 7 days prior to start of treatment. Women of childbearing potential
or men with partners of childbearing potential must use effective birth control
measures during treatment. If a woman becomes pregnant or suspects she is pregnant
while participating in this study, she must agree to inform her treating physician

12. INR ≤1.5 x institutional upper limit of normal (ULN) . (Anticoagulation is allowed if
target INR is ≤1.5 on a stable dose of warfarin or on a stable dose of LMW heparin
for >2 weeks at the time of study entry).

13. Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤2.5 x
institutional ULN. Note: In case one or both of these thresholds are exceeded, the
patient can only be included in the study after initiation of appropriate
lipid-lowering medication.

14. Patients must be accessible for treatment and follow-up.

15. Patients must be able to understand the investigational nature of this study and give
written informed consent prior to study entry.

Exclusion Criteria:

1. Previous treatment with bevacizumab or any other anti-angiogenesis agents.

2. Previous treatment with m-TOR inhibitors (sirolimus, temsirolimus, everolimus).

3. Patients who have had major surgery or significant traumatic injury within 4 weeks of
the start of study drugs, patients who have not recovered from the side effects of
any major surgery (defined as requiring general anesthesia), or patients that may
require major surgery during the course of the study.

4. Minor surgical procedures (with the exception of the placement of portacath or other
central venous access) must be completed at least 7 days prior to beginning protocol

5. Women who are pregnant or lactating.

6. Patients with proteinuria at screening as demonstrated by either:

urine protein creatinine (UPC) ratio 1.0 at screening OR urine dipstick for
proteinuria 2+ (patients discovered to have 2+ proteinuria on dipstick urinalysis at
baseline should undergo a 24-hour urine collection, and must demonstrate 1 g of
protein/24 hours to be eligible)

7. Patients with a serious non-healing wound, active ulcer, or untreated bone fracture.

8. Patients with evidence of bleeding diathesis or significant coagulopathy (in the
absence of therapeutic anticoagulation).

9. Patients with history of hematemesis or hemoptysis (defined as having bright red
blood of ½ teaspoon or more per episode) within 1 month prior to study enrollment.

10. History of myocardial infarction or unstable angina within 6 months of beginning

11. Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg
and /or diastolic blood pressure >100 mmHg while on antihypertensive medications).

12. New York Heart Association (NYHA) class II or greater congestive heart failure (CHF).

13. Serious cardiac arrhythmia requiring medication.

14. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or
recent peripheral arterial thrombosis) within 6 months prior to Day 1 of treatment.

15. History of stroke or transient ischemic attack within 6 months prior to beginning

16. Any prior history of hypertensive crisis or hypertensive encephalopathy.

17. History of abdominal fistula or gastrointestinal perforation within 6 months prior to
Day 1 of beginning treatment.

18. Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of everolimus (e.g., ulcerative disease,
uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel

19. Any severe and/or uncontrolled medical conditions or other conditions that could
affect participation in the study such as:

- unstable angina pectoris, symptomatic CHF, myocardial infarction within 6 months
of start of study drug, serious uncontrolled cardiac arrhythmia, or any other
clinically significant cardiac disease

- severely impaired lung function

- uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN

- active (acute or chronic) or uncontrolled severe infections

- liver disease such as cirrhosis, chronic active hepatitis or chronic persistent

20. Known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus),
or to its excipients.

21. Immunization with attenuated live vaccines within 1 week of the study, or anytime
during study treatment.

22. Chronic, systemic treatment with immunosuppressive agents. Patients who require a
stable dose of corticosteroids for control of cerebral edema are eligible. Topical or
inhaled steroids are also allowed.

23. Known human immunodeficiency virus (HIV) infection.

24. Grapefruits, star fruits, seville oranges, and their juices and products, should be

25. Drugs or substances known to be inhibitors or inducers of the isoenzyme CYP3A4 should
be avoided.

26. Use of St. John's Wort or rifampicin.

27. Concurrent severe, intercurrent illness including, but not limited to, ongoing or
active infection, or psychiatric illness/social situations that would limit
compliance with study requirements.

28. Mental condition that would prevent patient comprehension of the nature of, and risk
associated with, the study.

29. Use of any non-approved or investigational agent within 4 weeks of study entry.
Patients may not receive any other investigational or anti-cancer treatments while
participating in this study.

30. Other malignancies within the last 3 years, with the exception of adequately treated
basal or squamous cell carcinomas of the skin, or carcinoma in situ of the cervix.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the efficacy of the combination of bevacizumab and everolimus, by measurement of progression-free survival (PFS), in the treatment of patients with refractory meningioma.

Outcome Time Frame:

18 months

Safety Issue:


Principal Investigator

John D Hainsworth, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

January 2010

Completion Date:

December 2013

Related Keywords:

  • Intracranial Meningioma
  • Avastin
  • RAD001
  • Meningioma
  • Bevacizumab
  • Everolimus
  • Brain
  • Meningioma



University of Pittsburgh Medical Center Pittsburgh, Pennsylvania  15213
Peninsula Cancer Institute Newport News, Virginia  23601
Tennessee Oncology, PLLC Clarksville, Tennessee  37043
Norton Cancer Institute Louisville, Kentucky  40207
Nebraska Methodist Cancer Center Omaha, Nebraska  68114
Florida Hospital Cancer Insitute Orlando, Florida  32804
UT Cancer Insititute Memphis Memphis, Tennessee  38104